(Q40370520)

19 September 2017

title

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials (English)

1 reference

19 September 2017

Creutzig U

1

1 reference

19 September 2017

Zimmermann M

2

1 reference

19 September 2017

Ritter J

3

1 reference

19 September 2017

Reinhardt D

4

1 reference

19 September 2017

Hermann J

5

1 reference

19 September 2017

Henze G

6

1 reference

19 September 2017

Jürgens H

7

1 reference

19 September 2017

Kabisch H

8

1 reference

19 September 2017

Reiter A

9

1 reference

19 September 2017

Riehm H

10

1 reference

19 September 2017

Gadner H

11

1 reference

19 September 2017

Schellong G

12

1 reference

19 September 2017

publication date

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

19

1 reference

19 September 2017

issue

12

1 reference

19 September 2017

page(s)

2030-2042

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403920

19 September 2017

exact match

0 references

cites work

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

[Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a European view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

FLT3-TKD mutation in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Definition of a standard-risk group in children with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

3 × 14 mg/m2 Idarubicin during induction: results of a pilot study in children with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

[Therapy realization and complications in the BFM-83 therapy study of acute myelogenous leukemia]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Improved treatment results in children with AML: Results of study AML-BFM 93

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403920

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403920

1 reference

Dimensions Publication ID

19 September 2017

1038093844

0 references

1 reference